Pioneering therapies for rare diseases of abnormal mineralization.
Inozyme Pharma, founded in 2017 and headquartered in Boston, Massachusetts, was a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases characterized by abnormal mineralization. The company's lead program, INDEE, targeted ENPP1 deficiency, a life-threatening rare disease affecting the heart, vasculature, and skeleton. With approximately 50 employees, Inozyme went public on Nasdaq (INZY) before being acquired by BioMarin Pharmaceutical in May 2025 for $270 million.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account